Stifel Financial Corp Raises Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Stifel Financial Corp raised its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 1.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 69,134 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,093 shares during the period. Stifel Financial Corp’s holdings in Supernus Pharmaceuticals were worth $2,156,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Armistice Capital LLC grew its holdings in shares of Supernus Pharmaceuticals by 47.6% during the 2nd quarter. Armistice Capital LLC now owns 5,272,000 shares of the specialty pharmaceutical company’s stock worth $141,026,000 after purchasing an additional 1,700,000 shares during the period. Dimensional Fund Advisors LP lifted its position in Supernus Pharmaceuticals by 12.1% during the second quarter. Dimensional Fund Advisors LP now owns 2,866,887 shares of the specialty pharmaceutical company’s stock valued at $76,690,000 after buying an additional 309,966 shares in the last quarter. Stephens Investment Management Group LLC grew its stake in Supernus Pharmaceuticals by 1.8% during the third quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock worth $60,246,000 after buying an additional 33,710 shares during the period. Pacer Advisors Inc. increased its position in shares of Supernus Pharmaceuticals by 29.9% in the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock worth $54,655,000 after acquiring an additional 403,028 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Supernus Pharmaceuticals by 26.4% in the second quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company’s stock worth $45,077,000 after acquiring an additional 351,900 shares in the last quarter.

Supernus Pharmaceuticals Stock Up 0.9 %

Shares of NASDAQ:SUPN opened at $35.77 on Friday. The company has a 50 day moving average of $35.61 and a two-hundred day moving average of $32.16. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $39.37. The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of 33.43 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The business had revenue of $175.70 million during the quarter, compared to analyst estimates of $157.35 million. During the same period last year, the business earned ($0.29) EPS. The business’s revenue was up 14.2% on a year-over-year basis. On average, equities analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current year.

Insider Transactions at Supernus Pharmaceuticals

In other news, SVP Frank Mottola sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.98, for a total transaction of $554,700.00. Following the completion of the sale, the senior vice president now owns 8,200 shares of the company’s stock, valued at approximately $303,236. This trade represents a 64.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jack A. Khattar sold 125,000 shares of the company’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the completion of the sale, the chief executive officer now directly owns 926,172 shares in the company, valued at $33,971,988.96. This represents a 11.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 154,213 shares of company stock valued at $5,660,180. 9.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on SUPN shares. Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.